glp 1 monoclonal antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites Anti-GLP1 (7-36) antibody [EPR4042-1] -
Pay in 4 interest-free payments of $7.32 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
![glp 1 monoclonal antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites Anti-GLP1 (7-36) antibody [EPR4042-1] -](https://content.abcam.com/products/images/glp1-7-36-antibody-epr4042-1-bsa-and-azide-free-capture-ab244627--sandwich-elisa-img185602.jpg)
![glp 1 monoclonal antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites Anti-GLP1 (7-36) antibody [EPR4042-1] -](https://content.abcam.com/products/images/glp-1-antibody-11e2-ab23468--immunocytochemistry-immunofluorescence-img63062.jpg)
![glp 1 monoclonal antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites Anti-GLP1 (7-36) antibody [EPR4042-1] -](https://www.creative-diagnostics.com/upload/image/glp-1-glp-1r-the-star-target-for-type-2-diabetes-mellitus-treatment-2.jpg)
![glp 1 monoclonal antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites Anti-GLP1 (7-36) antibody [EPR4042-1] -](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00428-025-04098-2/MediaObjects/428_2025_4098_Fig1_HTML.png)
![glp 1 monoclonal antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites Anti-GLP1 (7-36) antibody [EPR4042-1] -](https://www.thermofisher.com/antibody/images/650/701296_WB.jpg?time=20240507)
![glp 1 monoclonal antibody Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites Anti-GLP1 (7-36) antibody [EPR4042-1] -](https://www.biointron.com/static/upload/image/industry/2024/MariTide-1.jpg)





















